BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Revolinski SL, Munoz-Price LS. Clostridium difficile in Immunocompromised Hosts: A Review of Epidemiology, Risk Factors, Treatment, and Prevention. Clin Infect Dis 2019;68:2144-53. [PMID: 30281082 DOI: 10.1093/cid/ciy845] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Revolinski S, Munoz-Price LS. Fecal Microbiota Transplantation for Clostridioides difficile Infection in Immunocompromised Hosts. Clin Infect Dis 2021;72:2247. [PMID: 32275059 DOI: 10.1093/cid/ciz689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ziegler MJ, Freyer C, Landsburg D, Pegues D, Bilker W, Hirsh R, Kucharczuk C, Gilmar C, Gorman T, Palmer M, Harker C, Lightheart E, Han JH. Guideline implementation is effective at reducing proton pump inhibitor use in hematology-oncology units: A multidisciplinary intervention for reducing Clostridioides difficile risk. Infect Control Hosp Epidemiol 2019;40:1294-6. [PMID: 31466535 DOI: 10.1017/ice.2019.238] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Keats KR, Stitt TM, Chastain DB, Jivan BP, Matznick E, Waller JL, Clemmons AB. Evaluating Clostridioides difficile infection (CDI) treatment duration in hematology/oncology patients receiving concurrent non-CDI antibiotics. J Oncol Pharm Pract 2021;:1078155221998735. [PMID: 33663290 DOI: 10.1177/1078155221998735] [Reference Citation Analysis]
4 Duhalde L, Lurienne L, Wingen-Heimann SM, Guillou L, Buffet R, Bandinelli PA. The economic burden of Clostridioides difficile infection in patients with hematological malignancies in the United States: A case-control study. Infect Control Hosp Epidemiol 2020;41:813-9. [PMID: 32408912 DOI: 10.1017/ice.2020.153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Dutta D, Jafri F, Stuhr D, Knoll BM, Lim SH. A contemporary review of Clostridioides difficile infections in patients with haematologic diseases. J Intern Med 2021;289:293-308. [PMID: 32910532 DOI: 10.1111/joim.13173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Alonso CD, Maron G, Kamboj M, Carpenter PA, Gurunathan A, Mullane K, Dubberke ER. American Society for Transplantation and Cellular Therapy Series: #5 - Management of Clostridioides difficile infection in hematopoietic cell transplant recipients. Transplant Cell Ther 2022:S2666-6367(22)00093-8. [PMID: 35202891 DOI: 10.1016/j.jtct.2022.02.013] [Reference Citation Analysis]
7 Poylin V, Hawkins AT, Bhama AR, Boutros M, Lightner AL, Khanna S, Paquette IM, Feingold DL; Prepared by the Clinical Practice Guidelines Committee of The American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection. Dis Colon Rectum 2021;64:650-68. [PMID: 33769319 DOI: 10.1097/DCR.0000000000002047] [Reference Citation Analysis]
8 Polage CR, Quan KA, Madey K, Myers FE, Wightman DA, Krishna S, Grein JD, Gibbs L, Yokoe D, Mabalot SC, Chinn R, Hallmark A, Rubin Z, Fontenot M, Cohen S, Birnbaum D, Huang SS, Torriani FJ. Evaluation of the National Healthcare Safety Network standardized infection ratio risk adjustment for healthcare-facility-onset Clostridioides difficile infection in intensive care, oncology, and hematopoietic cell transplant units in general acute-care hospitals. Infect Control Hosp Epidemiol 2020;41:404-10. [PMID: 32052726 DOI: 10.1017/ice.2020.4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Wong D, Nanda N. Clostridium difficile disease in solid organ transplant recipients: a recommended treatment paradigm. Curr Opin Organ Transplant 2020;25:357-63. [PMID: 32618715 DOI: 10.1097/MOT.0000000000000778] [Reference Citation Analysis]
10 De-la-rosa-martinez D, Rivera-buendía F, Cornejo-juárez P, García-pineda B, Nevárez-luján C, Vilar-compte D. Risk factors and clinical outcomes for Clostridioides difficile infections in a case control study at a large cancer referral center in Mexico. American Journal of Infection Control 2022. [DOI: 10.1016/j.ajic.2022.02.011] [Reference Citation Analysis]
11 Rzayev T, Yüksel Mayda P, Erkan T, Kocazeybek B, Kutlu T. Clostridium difficile Colonization Before and After Hospitalization in Children. Turk Arch Pediatr 2021;56:585-90. [PMID: 35110057 DOI: 10.5152/TurkArchPediatr.2021.21139] [Reference Citation Analysis]
12 Abukhalil AD, AbuKhdeir L, Hamed M, Al Shami N, Naseef HA, Aiesh BM, Sabateen A. Characteristics, Risk Factors, and Prevalence of Clostridioides difficile Among Hospitalized Patients in a Tertiary Care Hospital in Palestine. Infect Drug Resist 2021;14:4681-8. [PMID: 34785915 DOI: 10.2147/IDR.S333985] [Reference Citation Analysis]
13 Ruan W, Kellermayer R. Alternative Diagnoses in Pediatric Fecal Microbiota Transplant Referral Patients. J Pediatr Gastroenterol Nutr 2021;72:693-6. [PMID: 33534360 DOI: 10.1097/MPG.0000000000003060] [Reference Citation Analysis]
14 Stewart D, Anwar F, Vedantam G. Anti-virulence strategies for Clostridioides difficile infection: advances and roadblocks. Gut Microbes 2020;12:1802865. [PMID: 33092487 DOI: 10.1080/19490976.2020.1802865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Okamoto K, Santos CAQ. Management and prophylaxis of bacterial and mycobacterial infections among lung transplant recipients. Ann Transl Med 2020;8:413. [PMID: 32355857 DOI: 10.21037/atm.2020.01.120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Shenoy ES, Ramsey A. Carved in Stone with Consequences: Antibiotic Allergy Labels in Transplant Patients. Clin Infect Dis 2020;71:1595-7. [PMID: 31621837 DOI: 10.1093/cid/ciz1028] [Reference Citation Analysis]
17 Mendelsohn RB, Kaltsas A, King S, Hwang C, Kassam Z, Abend AM, Kramer E, Kamboj M. Fecal Microbiota Transplantation Is Safe for Clostridiodies difficile Infection in Patients with Solid Tumors Undergoing Chemotherapy. Dig Dis Sci 2021. [PMID: 34089134 DOI: 10.1007/s10620-021-07024-z] [Reference Citation Analysis]
18 Kulecka M, Waker E, Ambrozkiewicz F, Paziewska A, Skubisz K, Cybula P, Targoński Ł, Mikula M, Walewski J, Ostrowski J. Higher genome variability within metabolism genes associates with recurrent Clostridium difficile infection. BMC Microbiol 2021;21:36. [PMID: 33509087 DOI: 10.1186/s12866-021-02090-9] [Reference Citation Analysis]
19 Stohs E, Kalil AC. A Sepsis Screening Tool for Hematopoietic Cell Transplant Recipients Remains Elusive. Clin Infect Dis 2021;72:1230-1. [PMID: 32133484 DOI: 10.1093/cid/ciaa221] [Reference Citation Analysis]
20 Nana T, Moore C, Boyles T, Brink AJ, Cleghorn J, Devenish LM, du Toit B, Fredericks ES, Lekalakala-Mokaba MR, Maluleka C, Rajabally MN, Reubenson G, Shuping L, Swart K, Swe Han KS, Wadula J, Wojno J, Lowman W. South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection prevention and control guideline. S Afr J Infect Dis 2020;35:219. [PMID: 34485483 DOI: 10.4102/sajid.v35i1.219] [Reference Citation Analysis]
21 Yepez Guevara EA, Aitken SL, Olvera AV, Carlin L, Fernandes KE, Bhatti MM, Garey KW, Adachi J, Okhuysen PC. Clostridioides difficile Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes. Clin Infect Dis 2021;72:e460-5. [PMID: 32803229 DOI: 10.1093/cid/ciaa1184] [Reference Citation Analysis]
22 Hung YP, Tsai CS, Tsai BY, Tsai PJ, Lee YT, Lee JC, Liu HC, Hsueh PR, Lee CC, Ko WC. Clostridioides difficile infection in patients with hematological malignancy: A multicenter study in Taiwan. J Microbiol Immunol Infect 2021:S1684-1182(21)00045-1. [PMID: 33678554 DOI: 10.1016/j.jmii.2021.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Benech N, Sokol H. Expert centres for faecal microbiota transplantation: The guarantee for safe and effective use of faecal transplants. United European Gastroenterol J 2020;8:1145-6. [PMID: 33167783 DOI: 10.1177/2050640620970372] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Askar SF, Kenney RM, Tariq Z, Conner R, Williams J, Ramesh M, Alangaden GJ. Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection With a Focus on Immunocompromised Patients. J Pharm Pract 2022;:8971900221074929. [PMID: 35090351 DOI: 10.1177/08971900221074929] [Reference Citation Analysis]
25 Amjad W, Qureshi W, Malik A, Singh R, Jafri SM. The outcomes of Clostridioides difficile infection in inpatient liver transplant population. Transpl Infect Dis 2021;:e13750. [PMID: 34695277 DOI: 10.1111/tid.13750] [Reference Citation Analysis]
26 Alonso CD, Papamichael K, Sprague R, Barrett C, Gonzales-Luna AJ, Daugherty K, Garey KW, Villafuerte-Gálvez J, Xu H, Lin Q, Wang L, Chen X, Pollock NR, Kelly CP. Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection. Open Forum Infect Dis 2021;8:ofab286. [PMID: 34258317 DOI: 10.1093/ofid/ofab286] [Reference Citation Analysis]
27 Jorgenson MR, Descourouez JL, Yang DY, Leverson GE, Saddler CM, Smith JA, Safdar N, Mandlebrot DA, Redfield RR. Epidemiology, Risk Factors, and Outcomes After Early Posttransplant Clostridiodes difficile Infection in Renal Transplant Recipients. Ann Pharmacother 2019;53:1020-5. [PMID: 31007034 DOI: 10.1177/1060028019845003] [Reference Citation Analysis]
28 Kelly CR, Fischer M, Grinspan A, Allegretti JR. Patients Eligible for Trials of Microbe-Based Therapeutics Do Not Represent the Population With Recurrent Clostridioides difficile Infection. Clin Gastroenterol Hepatol 2020;18:1099-101. [PMID: 31254675 DOI: 10.1016/j.cgh.2019.06.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
29 Dalal NH, Dores GM, Curtis RE, Linet MS, Morton LM. Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016. Br J Haematol 2020;189:1107-18. [PMID: 32090327 DOI: 10.1111/bjh.16492] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Coccolini F, Improta M, Sartelli M, Rasa K, Sawyer R, Coimbra R, Chiarugi M, Litvin A, Hardcastle T, Forfori F, Vincent JL, Hecker A, Ten Broek R, Bonavina L, Chirica M, Boggi U, Pikoulis E, Di Saverio S, Montravers P, Augustin G, Tartaglia D, Cicuttin E, Cremonini C, Viaggi B, De Simone B, Malbrain M, Shelat VG, Fugazzola P, Ansaloni L, Isik A, Rubio I, Kamal I, Corradi F, Tarasconi A, Gitto S, Podda M, Pikoulis A, Leppaniemi A, Ceresoli M, Romeo O, Moore EE, Demetrashvili Z, Biffl WL, Wani I, Tolonen M, Duane T, Dhingra S, DeAngelis N, Tan E, Abu-Zidan F, Ordonez C, Cui Y, Labricciosa F, Perrone G, Di Marzo F, Peitzman A, Sakakushev B, Sugrue M, Boermeester M, Nunez RM, Gomes CA, Bala M, Kluger Y, Catena F. Acute abdomen in the immunocompromised patient: WSES, SIS-E, WSIS, AAST, and GAIS guidelines. World J Emerg Surg 2021;16:40. [PMID: 34372902 DOI: 10.1186/s13017-021-00380-1] [Reference Citation Analysis]
31 Non LR, Ince D. Infectious Gastroenteritis in Transplant Patients. Gastroenterol Clin North Am 2021;50:415-30. [PMID: 34024449 DOI: 10.1016/j.gtc.2021.02.013] [Reference Citation Analysis]
32 Abukhalil AD, Abukhdeir L, Hamed M, Al Shami N, Naseef HA, Aiesh BM, Sabateen A. Characteristics, Risk Factors, and Prevalence of Clostridioides difficile Among Hospitalized Patients in a Tertiary Care Hospital in Palestine. IDR 2021;Volume 14:4681-8. [DOI: 10.2147/idr.s333985] [Reference Citation Analysis]
33 Fettucciari K, Marconi P, Marchegiani A, Fruganti A, Spaterna A, Bassotti G. Invisible steps for a global endemy: molecular strategies adopted by Clostridioides difficile. Therap Adv Gastroenterol 2021;14:17562848211032797. [PMID: 34413901 DOI: 10.1177/17562848211032797] [Reference Citation Analysis]
34 Keegan J, Buchan BW, Ledeboer NA, Zhou Z, Hong JC, Graham MB, Munoz-Price LS. Toxigenic Clostridioides difficile colonization as a risk factor for development of C. difficile infection in solid-organ transplant patients. Infect Control Hosp Epidemiol 2021;42:287-91. [PMID: 32933595 DOI: 10.1017/ice.2020.431] [Reference Citation Analysis]
35 Bush K, Barbosa H, Farooq S, Weisenthal SJ, Trayhan M, White RJ, Noyes EI, Ghoshal G, Zand MS. Predicting hospital-onset Clostridium difficile using patient mobility data: A network approach. Infect Control Hosp Epidemiol 2019;40:1380-6. [PMID: 31656216 DOI: 10.1017/ice.2019.288] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]